Age-related macular degeneration (AMD) is among the most common retinal diagnoses. Although the clinical features of the disease are well known, ICD-10 coding can be confusing if details such as stage, activity, and laterality are not clearly documented. Incomplete documentation may prompt questions about the medical necessity of diagnostic tests or intravitreal injections. This Q&A addresses common sources of confusion and offers practical guidance to support clear, accurate documentation.
A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.